{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=12", "query": { "intervention": "antibody-drug conjugate", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T01:13:19.661Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1438, "start_date": "2025-08-12", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 19, "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" }, { "nct_id": "NCT06809114", "title": "FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "AT03-65", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Axcynsis Therapeutics Pte Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2026-01-14", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 4, "location_summary": "Denver, Colorado • New Haven, Connecticut • Portland, Oregon + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Portland", "state": "Oregon" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06809114" }, { "nct_id": "NCT02343406", "title": "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Depatuxizumab mafodotin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "99 Years", "sex": "ALL", "summary": "Up to 99 Years" }, "enrollment_count": 266, "start_date": "2015-02-17", "completion_date": "2019-06-24", "has_results": true, "last_update_posted_date": "2020-05-22", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 13, "location_summary": "Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343406" }, { "nct_id": "NCT06625593", "title": "A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-C137", "type": "DRUG" }, { "name": "Anticancer Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2024-12-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Rochester, Minnesota + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625593" }, { "nct_id": "NCT05875168", "title": "First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "DS-3939a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2023-08-18", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 12, "location_summary": "Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Locust Grove", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05875168" }, { "nct_id": "NCT05104866", "title": "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 732, "start_date": "2021-10-18", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05104866" }, { "nct_id": "NCT04316442", "title": "Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Light Chain (AL) Amyloidosis" ], "interventions": [ { "name": "STI-6129", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sorrento Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-04-01", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 4, "location_summary": "Duarte, California • Boston, Massachusetts • Detroit, Michigan + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04316442" }, { "nct_id": "NCT03650491", "title": "A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma With Failed Remission" ], "interventions": [ { "name": "FOR46", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fortis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2019-04-03", "completion_date": "2022-01-31", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650491" }, { "nct_id": "NCT01786096", "title": "A Safety Study of SGN-CD19A for Leukemia and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "Precursor B-cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "SGN-CD19A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 92, "start_date": "2013-02", "completion_date": "2017-05-30", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786096" }, { "nct_id": "NCT03575819", "title": "A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "FOR46", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fortis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 56, "start_date": "2019-02-04", "completion_date": "2023-11-22", "has_results": false, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-10-15T01:13:19.661Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575819" } ] }